

Celleron Therapeutics Appoints Corporate Governance Expert, Katherine Innes Ker, To Board

Oxford, UK, 8 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the appointment of Dr Katherine Innes-Ker to its Board of Directors.

Dr Katherine Innes Ker BA (Hons), DPhil, has been appointed as a Non-Executive Director to the Board of cancer biotech Celleron Therapeutics, Oxford, UK. In addition to a DPhil in Molecular Biophysics, Katherine is a highly experienced Non-Executive Director, and committee chair across a range of sectors, with extensive experience of the City of London markets. Notably she is Remuneration Chairman, for Balliol College, University of Oxford and was a member of the Management Board of the Bonavero Institute of Human Rights, University of Oxford.

Professor Nick La Thangue, Co-founder and Chief Executive Officer of Celleron Therapeutic, commented: *“We are delighted that Katherine is joining the Celleron Board of Directors. Her depth of knowledge and experience will certainly strengthen the governance team, and extend our existing ties within the UK investment community”*.

Dr Katherine Innes Ker BA (Hons), DPhil, commented: *“I am delighted to join the Board of Celleron Therapeutics and look forward to assisting the management in progressing the development of their growing portfolio of targeted cancer therapeutics”*.

About Celleron Therapeutics Limited

Celleron Therapeutics is a biopharma advancing a clinical and pre-clinical pipeline of precision therapies for different cancer indications. The company is located on the Oxford Science Park, UK. Celleron Therapeutics has built a proprietary platform around epigenetic control and immune modulation, providing its drugs with a two-pronged attack on cancer. Celleron’s approach seeks to align the right drug with the right patient enabling a personalised approach to cancer therapy. Celleron Therapeutics’ focus is on those cancers where there is still an unmet need for long-term disease control. It is hoped that not only will patients volunteering for our clinical trials benefit directly, but the results from these studies will ultimately allow the general use of more effective, safer medicines. Our goal is not only to treat cancer, but improve quality of life during therapy by reduction of side effects.

Celleron has global license partnerships with Astra Zeneca and Roche. The company secured investment in 2016 from a consortium of South Korean investors; and in 2020 spun out an affiliate company, SynOx Therapeutics.

For more information see <https://cellerontherapeutics.com>